Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | BX-912 | 1 | 72 | 3.2 | 884.5 | 3461.8 | 1279.8 | 0.505 | -0.227 | 0.256 | 1.436 | HCC70 BX912 0 1 72 |
| HCC70 | Alpelisib | 1 | 72 | 0.001 | 3470.5 | 3338.5 | 1279.8 | -3.0 | 1.060 | 1.040 | 1.383 | HCC70 BYL719 0 1 72 |
| HCC70 | Alpelisib | 1 | 72 | 0.0032 | 2960.5 | 3338.5 | 1279.8 | -2.49 | 0.834 | 0.887 | 1.383 | HCC70 BYL719 0 1 72 |
| HCC70 | Alpelisib | 1 | 72 | 0.01 | 3355.5 | 3338.5 | 1279.8 | -2.0 | 1.010 | 1.010 | 1.383 | HCC70 BYL719 0 1 72 |
| HCC70 | Alpelisib | 1 | 72 | 0.032 | 3188.8 | 3338.5 | 1279.8 | -1.49 | 0.935 | 0.955 | 1.383 | HCC70 BYL719 0 1 72 |
| HCC70 | Alpelisib | 1 | 72 | 0.1 | 3180.5 | 3338.5 | 1279.8 | -1.0 | 0.931 | 0.953 | 1.383 | HCC70 BYL719 0 1 72 |
| HCC70 | Alpelisib | 1 | 72 | 0.32 | 3230.8 | 3338.5 | 1279.8 | -0.495 | 0.953 | 0.968 | 1.383 | HCC70 BYL719 0 1 72 |
| HCC70 | Alpelisib | 1 | 72 | 1.0 | 2870.0 | 3338.5 | 1279.8 | 0.0 | 0.793 | 0.860 | 1.383 | HCC70 BYL719 0 1 72 |
| HCC70 | Alpelisib | 1 | 72 | 3.2 | 2397.8 | 3338.5 | 1279.8 | 0.505 | 0.574 | 0.718 | 1.383 | HCC70 BYL719 0 1 72 |
| HCC70 | CAL-101 | 1 | 72 | 0.001 | 3443.3 | 3340.3 | 1279.8 | -3.0 | 1.040 | 1.030 | 1.384 | HCC70 CAL101 0 1 72 |
| HCC70 | CAL-101 | 1 | 72 | 0.0032 | 3458.8 | 3340.3 | 1279.8 | -2.49 | 1.050 | 1.040 | 1.384 | HCC70 CAL101 0 1 72 |
| HCC70 | CAL-101 | 1 | 72 | 0.01 | 3348.8 | 3340.3 | 1279.8 | -2.0 | 1.000 | 1.000 | 1.384 | HCC70 CAL101 0 1 72 |
| HCC70 | CAL-101 | 1 | 72 | 0.032 | 3230.5 | 3340.3 | 1279.8 | -1.49 | 0.952 | 0.967 | 1.384 | HCC70 CAL101 0 1 72 |
| HCC70 | CAL-101 | 1 | 72 | 0.1 | 3385.5 | 3340.3 | 1279.8 | -1.0 | 1.020 | 1.010 | 1.384 | HCC70 CAL101 0 1 72 |
| HCC70 | CAL-101 | 1 | 72 | 0.32 | 3108.3 | 3340.3 | 1279.8 | -0.495 | 0.899 | 0.931 | 1.384 | HCC70 CAL101 0 1 72 |
| HCC70 | CAL-101 | 1 | 72 | 1.0 | 2636.8 | 3340.3 | 1279.8 | 0.0 | 0.686 | 0.789 | 1.384 | HCC70 CAL101 0 1 72 |
| HCC70 | CAL-101 | 1 | 72 | 3.2 | 2212.3 | 3340.3 | 1279.8 | 0.505 | 0.485 | 0.662 | 1.384 | HCC70 CAL101 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 0.001 | 2591.0 | 3299.0 | 1279.8 | -3.0 | 0.676 | 0.785 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 0.0032 | 2698.8 | 3299.0 | 1279.8 | -2.49 | 0.727 | 0.818 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 0.01 | 2542.0 | 3299.0 | 1279.8 | -2.0 | 0.653 | 0.771 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 0.032 | 2488.8 | 3299.0 | 1279.8 | -1.49 | 0.627 | 0.754 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 0.1 | 2470.0 | 3299.0 | 1279.8 | -1.0 | 0.618 | 0.749 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 0.32 | 2503.0 | 3299.0 | 1279.8 | -0.495 | 0.634 | 0.759 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 1.0 | 2518.5 | 3299.0 | 1279.8 | 0.0 | 0.641 | 0.763 | 1.366 | HCC70 Everolimus 0 1 72 |
| HCC70 | Everolimus | 1 | 72 | 3.2 | 2369.0 | 3299.0 | 1279.8 | 0.505 | 0.569 | 0.718 | 1.366 | HCC70 Everolimus 0 1 72 |